Access Signs OraDisc to a Licensing Agreement for the United States

Access Pharmaceuticals announced that it has executed an exclusive license agreement granting Discus Dental, Inc. the U.S. marketing rights for amlexanox. The rights granted are the amlexanox 5 percent paste, currently marketed in the United States for the treatment of canker sores and OraDisc A, which was approved by the FDA in 2004 for the same indication. In addition, Discus Dental has the rights to any future product improvements for amlexanox in oral disease. Under the terms of this agreement, Discus Dental will pay a licensing fee and will make milestone payments which, in total, could reach $10.8 million.

Yahoo News (http://biz.yahoo.com/prnews/050418/dam032.html?.v=7)